Baseline circulating IL-17 predicts toxicity while TGF-?1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.
Baseline circulating IL-17 predicts toxicity while TGF-?1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015; 3:39.